STAAR SURGICAL CO
For the period ended Dec 27, 2024. Filed Feb 21, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 21, 2025
STAA$23.87-2.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEM ENTS OF CASH FLOWS
| 2024 | 2023 | 2022 | |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net income (loss) | $(20,208) | $21,347 | $39,665 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||
| Depreciation of property, plant, and equipment | 6,891 | 5,111 | 4,481 |
| Amortization of intangibles | — | 13 | 28 |
| Impairment of intangibles | — | 154 | — |
| Accretion/amortization of investments available for sale | (1,091) | (2,501) | (1,198) |
| Deferred income taxes | 3,590 | 3,264 | (2,254) |
| Change in net pension liability | 26 | (956) | 53 |
| Loss on disposal of property and equipment | 1,694 | 73 | 65 |
| Stock-based compensation expense | 27,210 | 23,516 | 20,371 |
| Change in asset retirement obligation | (53) | (102) | 47 |
| Provision for sales returns and credit losses | 286 | 663 | 913 |
| Inventory provision | 2,782 | 4,851 | 2,423 |
| Changes in working capital: | |||
| Accounts receivable | 16,493 | (32,760) | (19,601) |
| Inventories | (10,000) | (14,361) | (7,943) |
| Prepayments, deposits, and other assets | (15,363) | (3,413) | (2,549) |
| Accounts payable | 75 | (701) | 1,805 |
| Other current liabilities | 3,393 | 10,396 | (591) |
| Net cash provided by operating activities | 15,725 | 14,594 | 35,715 |
| Cash flows from investing activities: | |||
| Acquisition of property and equipment | (23,394) | (18,188) | (18,108) |
| Purchase of investments available for sale | (80,240) | (52,313) | (155,748) |
| Proceeds from maturity of investments available for sale | 43,103 | 143,548 | 17,121 |
| Proceeds from sale of investments available for sale | 1,314 | 1,300 | 359 |
| Net cash provided by (used in) investing activities | (59,217) | 74,347 | (156,376) |
| Cash flows from financing activities: | |||
| Repayment of finance lease obligations | (165) | (161) | (126) |
| Repurchase of employee common stock for taxes withheld | (1,505) | (2,097) | — |
| Proceeds from the exercise of stock options | 7,392 | 9,672 | 8,422 |
| Proceeds from vested restricted stock | 2 | 1 | 1 |
| Net cash provided by financing activities | 5,724 | 7,415 | 8,297 |
| Effect of exchange rate changes on cash and cash equivalents | (1,111) | 202 | (862) |
| Increase (decrease) in cash and cash equivalents | (38,879) | 96,558 | (113,226) |
| Cash and cash equivalents, at beginning of year | 183,038 | 86,480 | 199,706 |
| Cash and cash equivalents, at end of year | $144,159 | $183,038 | $86,480 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.